A prospective study to evaluate bone health, FRAX score and quality of life in patients of carcinoma prostate.

King George Medical University0 sites80 target enrollmentTBD

ConditionsHealth Condition 1: null- Prostate cancer patients who presents to KGMU for treatment will be enrolled in the study.

Overview

Phase: N/A
Intervention: Not specified
Conditions: Health Condition 1: null- Prostate cancer patients who presents to KGMU for treatment will be enrolled in the study.
Sponsor: King George Medical University
Enrollment: 80
Status: Recruiting
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

4 years ago

Study Type

Observational

Investigators

Sponsor

King George Medical University

Eligibility Criteria

Inclusion Criteria

•1\.Diagnosed cases of prostate cancer

Exclusion Criteria

•1\.Other active malignancy
•2\.Metabolic bone disease

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting

Phase 1

study to assess the changes in bone health after changing from a TDF based regimen to Bicetegravir-Tenofovir Alafenamide-Emtricitavine based treatment

EUCTR2018-004499-36-ESConsorci Mar Parc de Salut de Barcelona60

Completed

N/A

Prospective cohort study on bone mineral dencity changes in the Stage 1,2 gastric cancer patients after gastrectomy

JPRN-UMIN000018957Japanese Gastirc cancer association220

Completed

N/A

A clinical study to evaluate the efficacy of bone-modyfying agent for the patients of prostate cancer.

JPRN-UMIN000015126Department of Urology, Keio University School of Medicine

Completed

N/A

Assessment of bone related bio-markers in patients with rheumatoid arthritis treated with Certolizumab pegolrheumatoid arthritis

JPRN-UMIN000029594Graduate School of Medicine, Osaka University Department of Respiratory Medicine and Clinical Immunology40

Active, Not Recruiting

Phase 1

ong-term bone mineral density follow-up in subjects completing PRIMROSE 1 or PRIMROSE 2Treatment of heavy menstrual bleeding associated with uterine fibroids.MedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]

EUCTR2021-000452-19-BGObsEva S.A.400